ACSS3（酰基辅酶A合成酶短链家族成员3）存在于许多组织中，与肿瘤细胞类型的发育和转移有关。我们对ACSS3进行了全面的泛癌分析。 TCGA（癌症基因组图谱）、CPTAC（临床蛋白质组学肿瘤分析联盟）和 HPA 数据库用于确定 ACSS3 与各种类型肿瘤之间的联系。 TCGA 数据库中的基因将使用 cBioPortal 查询进行识别，然后使用 GEO 数据验证它们的转录组表达。使用 TISCH 数据库的单细胞测序数据分析了大多数癌症类型的各种肿瘤组织中的 ACSS3 表达和细胞定位。根据HPA和CPTAC数据库，我们分析和评估了蛋白表达水平。基于使用 TCGA 数据库预测的 26 种癌症类型的 ACSS3 表达水平的精确生存数据进行预测分析。此外，我们利用TIMER和TISCH数据库研究了ACSS3与不同肿瘤组织中免疫微环境之间的关系。 CellMiner、GDSC 和 CTRP 数据将阐明 ACSS3 与耐药性之间的关系，并探索影响 ACSS3 表达的化学物质。我们研究的最后一部分探讨并验证了ACSS3在胶质瘤增殖、迁移和侵袭中的作用。ACSS3在多种肿瘤中存在差异表达，具有早期诊断价值。 ACSS3 表达与临床特征相关，高 ACSS 表达预示多种肿瘤的预后较差，并可能影响药物敏感性。胶质瘤免疫抑制微环境的变化与ACSS3的上调密切相关。ACSS3可以通过调节免疫微环境影响生物学过程，是预测不同人类癌症预后的新型生物标志物。 ACSS3 是神经胶质瘤的一个关键预后因素，与其增殖、迁移和侵袭有关。© 2024 作者。由爱思唯尔有限公司出版

ACSS3 (acyl-CoA synthetase short-chain family member 3) is found in numerous tissues and is linked to tumor cell type development and metastasis.We conducted a comprehensive pan-cancer analysis of ACSS3. The TCGA (Cancer Genome Atlas), CPTAC (Clinical Proteomic Tumor Analysis Consortium), and HPA databases were used to ascertain the connection between ACSS3 and various types of tumors. Genes in the TCGA database would be identified using cBioPortal queries, and their transcriptome expression would then be verified using GEO data. ACSS3 expression and cellular localization in various tumor tissues of most cancer types were analyzed using single-cell sequencing data from the TISCH database. According to HPA and CPTAC databases, we analyzed and evaluated protein expression levels. Predictive analysis based on precise survival data of ACSS3 expression levels for 26 cancer types predicted using the TCGA database. Furthermore, we investigated the relationship between ACSS3 and immune microenvironments in different tumor tissues using the TIMER and TISCH databases. CellMiner, GDSC, and CTRP data would clarify the relationship between ACSS3 and drug resistance and explore the chemicals that affect ACSS3 expression. The final part of our study explored and validated the role ACSS3 played in glioma proliferation, migration, and invasion.ACSS3 is differentially expressed in various tumors and exhibits early diagnostic value. ACSS3 expression is associated with clinical features, and high ACSS expression anticipates a worse prognosis in multiple tumors and may impact drug sensitivity. The changes in the immunosuppressive microenvironment of gliomas are closely related to the upregulation of ACSS3.ACSS3 is a novel biomarker for forecasting different human cancer prognoses, as it can influence the biological process by modulating the immune microenvironment. ACSS3 is a critical prognostic factor for glioma and is related to its proliferation, migration, and invasion.© 2024 The Authors. Published by Elsevier Ltd.